You are currently on the new version of our website. Access the old version .
PharmaceuticalsPharmaceuticals
  • Correction
  • Open Access

9 June 2025

Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595

,
,
,
,
,
,
,
,
1
Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, 70124 Bari, Italy
2
Division of Hematology and Stem Cell Transplantation, Policlinico “G. Rodolico-San Marco”, 95123 Catania, Italy
3
Hematology Unit, Ospedale Cardarelli, 80131 Napoli, Italy
4
Department of Hematology, Businco Hospital, 09121 Cagliari, Italy

Error in Surname

In the original publication [1], there surname of author Roberta Della Pepa should be Della Pepa.

Error in Table

In the original publication [1], there was a mistake in Table 1 as published. The number of patients with normal and elevated LDH is 59 (72) and 23 (28), respectively (instead of 23 (28) and 59 (72)). The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Sgherza, N.; Battisti, O.; Curci, P.; Conticello, C.; Palmieri, S.; Derudas, D.; Germano, C.; Martino, E.A.; Mele, G.; Della Pepa, R.; et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.